Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Key Points

• This study aims to compare the efficacy of pembrolizumab plus axitinib versus sunitinib in patients with advanced renal-cell carcinoma.
• Randomized trial conducted among previously untreated patients with advanced renal-cell carcinoma.
• Patients received either pembrolizumab plus axitinib or sunitinib.
• Clinical outcomes measured included overall survival, progression-free survival, and objective response rate.
• Pembrolizumab plus axitinib resulted in significantly longer overall survival compared to sunitinib.
• Progression-free survival was also significantly longer in the pembrolizumab plus axitinib group.
• The combination treatment yielded a higher objective response rate compared to sunitinib.